{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:11:13Z","timestamp":1789153873266,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011353","name":"Center for Clinical and Translational Science, University of Massachusetts","doi-asserted-by":"publisher","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}],"id":[{"id":"10.13039\/100011353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.amjcard.2023.07.139","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T06:53:54Z","timestamp":1691823234000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Clinical Response to Tumor Necrosis Factor-\u03b1 Inhibitor Therapy in the Management of Cardiac Sarcoidosis"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-5492","authenticated-orcid":false,"given":"Robert","family":"Churchill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Castrichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Arment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Myasoedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elwazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-0233","authenticated-orcid":false,"given":"Andrew","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.07.139_bib0001","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","article-title":"Detection of myocardial damage in patients with sarcoidosis","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0003","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0004","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis \u2015 digest version","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2147\/TCRM.S967","article-title":"Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis","volume":"4","author":"Callejas-Rubio","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0006","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them","volume":"25","author":"Baughman","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0007","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/art.21468","article-title":"Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis","volume":"53","author":"Sweiss","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0008","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","article-title":"Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","article-title":"Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: A multicenter experience","volume":"27","author":"Gilotra","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2021.02.022","article-title":"Effectiveness and safety of infliximab in cardiac Sarcoidosis","volume":"330","author":"Bakker","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0012","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.semarthrit.2019.11.004","article-title":"TNF-alpha inhibition for the treatment of cardiac sarcoidosis [published correction appears in SeminArthritis Rheum 2021;51:1390]","volume":"50","author":"Baker","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0013","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/heartjnl-2019-316442","article-title":"Cardiac sarcoidosis: state-of-the-art review","volume":"107","author":"Kouranos","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0014","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti\u2013tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(02)00470-9","article-title":"How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH","volume":"86","author":"Anker","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0017","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2008.09.009","article-title":"Cardiac sarcoidosis","volume":"157","author":"Kim","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0019","first-page":"36","article-title":"Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis","volume":"115","author":"Baughman","year":"1990","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0020","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1536\/ihj.21-164","article-title":"Cytokine signaling and matrix remodeling pathways associated with cardiac sarcoidosis disease activity defined using FDG PET imaging","volume":"62","author":"Young","year":"2021","journal-title":"Int Heart J"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0022","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2021.04.022","article-title":"Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease","volume":"335","author":"Rosenbaum","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0023","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"Harper","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.139_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.676407","article-title":"Case report: TNF\u03b1 antagonists are an effective therapy in cardiac sarcoidosis","volume":"8","author":"Stievenart","year":"2021","journal-title":"Front Cardiovasc Med"}],"updated-by":[{"DOI":"10.1016\/j.amjcard.2026.03.022","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000}}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923006951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923006951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:20:04Z","timestamp":1776180004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923006951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":24,"alternative-id":["S0002914923006951"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.139","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Response to Tumor Necrosis Factor-\u03b1 Inhibitor Therapy in the Management of Cardiac Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}